ALTAO.PA Aton

Healthcare Biotechnology Euronext Paris
0.0070 EUR
Close of Nov 8, 2026
0.0050 0.0290
Market cap
EUR 7.90M
P/E
-
P/B
11.58x
ROE
-2,600.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is ALTAO.PA undervalued?

Graham number

The Graham number of Aton cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Aton fundamental analysis

No fundamental analysis for Aton yet.

Aton stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Aton

Aton operates as a bioscience company in France. It engages in preclinical and clinical services, production of monoclonal antibodies, and laboratory equipment production, as well as provision of human tissues. The company is involved in development of biomaterials and reagents for diagnostics, as well as preclinical research services. Aton was founded in 1998 and is headquartered in Strasbourg, France.

Full company profile